PTC Therapeutics (PTCT) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed PTC Therapeutics (PTCT) over the past year, gaining 304.8% versus a loss of 2.0%. Over five years, PTCT leads with a +69.9% price change compared with -58.1% for SYRE. Spyre Therapeutics is the larger company by market cap ($8.01 billion vs $5.40 billion), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PTCT | SYRE |
|---|---|---|
| Share price | $64.70 | $85.69 |
| Market cap | $5.40B | $8.01B |
| 1-day change | +3.42% | +7.25% |
| YTD return | -14.82% | +161.57% |
| 1-year return | -1.98% | +304.77% |
| 5-year return | +69.86% | -58.10% |
| Forward P/E | 27.30 | — |
| EPS (TTM) | $-0.67 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.73B | $0 |
| Revenue growth (YoY) | +114.51% | — |
| Net income (latest FY) | $682.64M | $-155.20M |
| Operating margin | 50.09% | — |
| Net margin | 39.44% | — |
| 52-week high | $90.87 | $110.18 |
| 52-week low | $61.23 | $18.12 |
| Distance from 52-week high | -28.80% | -22.22% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +56.21% | +40.28% |
| Average volume | 1.14M | 1.22M |
| Shares outstanding | 83.46M | 93.45M |
| Employees | 991 | 125 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed PTCT by 306.8 percentage points over the past year.
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 125 employees
PTCT vs SYRE FAQ
Which is bigger, PTC Therapeutics or Spyre Therapeutics?
Spyre Therapeutics (SYRE) is larger, with a market capitalization of $8.01B compared with $5.40B for PTC Therapeutics (PTCT).
Which stock has performed better over the past year, PTCT or SYRE?
SYRE returned +304.77% over the past 12 months, compared with -1.98% for PTCT (price return, excluding dividends). Past performance does not predict future results.
Are PTC Therapeutics and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.